IP Library Granted Patent US 7,456,206
Granted Patent B2
US 7,456,206 · App. 11/486,769 · Granted Nov 25, 2008

Biaryl heterocyclic compounds and methods of making and using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,456,206
App. No.
11/486,769
Granted
Nov 25, 2008
Kind
B2
Abstract

The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of compounds having both a biaryl moiety and at least one heterocylic moiety that are useful as such agents.

Claims (14)

1. A compound having the structure

2. A tautomer of a compound having the structure

3. A pharmaceutically acceptable salt of a compound having the structure

4. The salt of claim 3 , wherein the salt is a non-toxic inorganic or organic acid salt of a compound having the structure

5. The salt of claim 4 , wherein the nontoxic inorganic or organic acid is selected from 2-acetoxybenzoic, 2-hydroxyethane sulfonic, acetic, ascorbic, benzene sulfonic, benzoic, bicarbonic, carbonic, citric, edetic, ethane disulfonic, ethane sulfonic, fumaric, glucoheptonic, gluconic, glutamic, glycolic, glycollyarsanilic, hexylresorcinic, hydrabamic, hydrobromic, hydrochloric, hydroiodic, hydroxymaleic, hydroxynaphthoic, isethionic, lactic, lactobionic, lauryl sulfonic, maleic, malic, mandelic, methane sulfonic, napsylic, nitric, oxalic, pamoic, pantothenic, phenylacetic, phosphoric, polygalacturonic, propionic, salicyclic, stearic, subacetic, succinic, sulfamic, sutfanilic, sulfuric, tannic, tartaric, and toluene sulfonic.

6. The salt of claim 4 , wherein the acid is hydrochloric.

7. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

8. A pharmaceutical composition comprising the tautomer of claim 2 and a pharmaceutically acceptable carrier.

9. A pharmaceutical composition comprising the salt of claim 3 and a pharmaceutically acceptable carrier.

10. A method of ameliorating a symptom of a microbial infection in a mammal comprising the step of administering to the mammal an effective amount of a compound or composition according to any one of claims 1 - 9 .

11. The method according to claim 10 , wherein the compound is administered orally, parentally, or topically.

12. A method of ameliorating a symptom of a disorder in a mammal comprising the step of administering to the mammal an effective amount of a compound or composition according to any one of claims 1 - 9 wherein the disorder is selected from the group consisting of: a skin infection, nosocomial pneumonia, post-viral pneumonia, an abdominal infection, a urinary tract infection, bacteremia, septicemia, endocarditis, an atrio-ventricular shunt infection, a vascular access infection, meningitis, a peritoneal infection, a bone infection, a joint infection, a methicillin-resistant Staphylococcus aurens infection, a vancomycin-resistant Enterococci infection, a linezolid-resistant organism infection, and tuberculosis.

13. The method according to claim 12 , wherein the compound is administered orally, parentally, or topically.

14. A method of ameliorating a symptom of microbial infection in a mammal by administering to the mammal prior to undergoing a surgical procedure an effective amount of a compound or composition according to any one of claims 1 - 9 .

Assignments (7)
AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Aug 25, 2022
From: MELINTA SUBSIDIARY CORP.
To: SILICON VALLEY BANK
Reel/Frame 061314/0572 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 22, 2020
From: MELINTA SUBSIDIARY CORP.
To: SILICON VALLEY BANK
Reel/Frame 054836/0824 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2019
From: MELINTA THERAPEUTICS, INC.
To: MELINTA SUBSIDIARY CORP.
Reel/Frame 048030/0489 →
SECURITY INTEREST Recorded Jan 8, 2018
From: MELINTA THERAPEUTICS, INC.; REMPEX PHARMACEUTICALS, INC.; CEMPRA PHARMACEUTICALS, INC.; CEM-102 PHARMACEUTICALS, INC.
To: CORTLAND CAPITAL MARKET SERVICES LLC, AS AGENT
Reel/Frame 045019/0552 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2014
From: ZHOU, JIACHENG; BHATTACHARJEE, ASHOKE; CHEN, SHILI; CHEN, YI; FARMER, JAY J.; GOLDBERG, JOEL A.; HANSELMANN, ROGER; LOU, RONGLIANG; ORBIN, ALIA; OYELERE, ADEGBOYEGA K.; SALVINO, JOSEPH M.; TRAN, JENNIFER; WANG, DEPING; WU, YUSHENG
To: RIB-X PHARMACEUTICALS, INC.
Reel/Frame 033811/0114 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2014
From: SPRINGER, DANE M.
To: RIB-X PHARMACEUTICALS, INC.
Reel/Frame 033811/0144 →
CHANGE OF NAME Recorded Sep 24, 2014
From: RIB-X PHARMACEUTICALS, INC.
To: MELINTA THERAPEUTICS, INC.
Reel/Frame 033813/0633 →